Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mapreg Post-Traumatic recovery program
- Development stage
- Preclinical
- Lead developer
- Mapreg
- Modality
- Small Molecules
01
Overview
Mapreg's Post-Traumatic recovery program involves a blood-brain barrier (BBB)-penetrant small molecule ligand targeting microtubule-associated protein 2 (MAP-2). MAP-2 is a protein primarily enriched in dendrites and serves as a critical marker for synaptic plasticity. Following traumatic brain injury, MAP-2 levels and distribution are often altered, impacting neuronal structural integrity. This therapeutic candidate is designed to modulate the MAP-2/microtubule interaction to facilitate neuroplasticity and functional recovery. It is currently in the preclinical stage of development as part of Mapreg's pipeline of neuroplastogen therapeutics.
- Other names
- Post-Traumatic recovery programMapreg MAP-2 small molecule
Beyond the preview
Go deeper on Mapreg Post-Traumatic recovery program.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mapreg Post-Traumatic recovery program.